Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DT Polio is a combination vaccine developed by Sanofi Pasteur for active immunization against diphtheria, tetanus, and poliomyelitis. It contains purified diphtheria toxoid, purified tetanus toxoid, and inactivated poliovirus (IPV) types 1, 2, and 3. A key characteristic of DT Polio is its standard concentration of diphtheria toxoid, which distinguishes it from low-dose formulations like REVAXIS. The vaccine is primarily indicated for booster vaccination in children who have previously completed a primary immunization series. It works by stimulating the immune system to produce neutralizing antibodies against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, as well as providing immunity against the three types of poliovirus. It is administered as an intramuscular injection and has been evaluated in Phase 3 trials for use as a second booster in 6-year-old children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DT Polio.